iKang Healthcare Group Launches End-to-End Managed Health Screening Service Powered by Precision Medicine and Strategic Partnerships

Having Trouble Understanding Your Health Checkup Report? How to Follow Up and Confirm Abnormal Findings. How to Access Specialized Medical Resources After a Cancer Diagnosis Post-Checkup? The pain point of “no follow-up care after health checkups” finally has a solution. Recently, at iKang Group’s strategic upgrade press conference, iKang innovatively introduced the concept of “managed health checkups,” along with the iKangCare+ and iKangPartners+ programs.

Mr. Zhang Ligang, Founder, Chairman, and CEO of iKang Group, stated:212 of the Fortune Global 500 companies operating in China and 89 of the Forbes China Top 100 companies have chosen iKang as their health management service provider.Through innovative upgrades to its products and services, iKang has addressed industry pain points and met the genuine needs of corporate clients’ employees, truly transforming health checkups into comprehensive health management services.

Mr. Zhang Ligang, Founder, Chairman, and CEO of iKang Group, Introduces the Concept of “Managed” Health Checkups

For health checkups that are “managed,” how exactly is this management carried out? At the press conference, iKang Group presented its answer with the launch of iKangCare+, a solution that will continue to be upgraded and iterated in the future. iKang will achieve this throughCorporate Client Tiered Service System，Connecting Customers by Integrating Precision Medicine and Artificial Intelligence, thereby providing enterprise-level clients with expert-grade health management services.

Following a medical check-up, many people have experienced difficulty understanding the obscure technical terminology in their reports. Moreover, numerous HR professionals and employee benefits managers receive inquiries from employees expressing concern over the lack of follow-up care or guidance after their examinations.。

Recognizing these tangible needs, iKang aims to connect with customers comprehensively from multiple perspectives to meet their requirements. Therefore, the iKangCare+ tiered service system for corporate clients provides access to the iKang App, official WeChat account, nationwide health checkup centers, a 400 hotline, and on-site services, offering professional and detailed interpretation of health checkup reports.

In an era where cancer inspires widespread fear, particularly with the rising incidence of high-prevalence malignancies such as lung cancer, gastrointestinal cancers, breast cancer, and cervical cancer, everyone hopes to detect early warning signs through health screenings. But how can one select screening items to achieve personalized detection?, once abnormal indicators are detected during a physical examination, how to proceed with follow-up tests and confirmatory diagnosis becomes a difficult problem facing people。

Driven by a deep understanding of this pain point, the iKangCare+ tiered corporate client service system recommends personalized specialized examinations based on employees’ historical health checkup results prior to their appointments. Post-examination, it not only provides targeted in-depth screening items based on abnormal findings but also continuously upgrades its positive result tracking system, thereby ensuring that every checkup is genuinely managed with dedicated follow-up care.

iKang Launches New “Triple Cancer-Prevention” Products

Regarding the management of abnormalities detected during health checkups, iKang has upgraded its solutions for high-incidence cancers based on its health checkup packages by integrating China’s leading disease detection technologies, introducing iKang’s “Three Treasures for Cancer Prevention.” For early screening of gastric and colorectal cancers, iKang’s “Gastrointestinal Treasure” incorporates China’s first fecal Helicobacter pylori genotyping test and a stool DNA test for early colorectal cancer screening.

For early screening of lung cancer, which has the highest incidence rate among cancers in China, iKang’s “Lung Care” package includes liquid biopsy for detecting ultra-early-stage lung cancer, low-dose computed tomography (CT) of the lungs, and genetic testing.

For more comprehensive early cancer screening and disease risk assessment, iKang’s “Jun Kang Bao” includes a full panel of genetic tests (197 items for men and 202 items for women), liquid biopsies for 18 high-incidence cancers, and lung CT scans.

To address the pain point of patients being diagnosed with cancer after health screenings yet lacking access to specialized medical resources, iKang continuously integrates premium industry resources to bridge the gap between clients and medical experts.Under the iKangCare+ tiered service system for corporate clients, if employees are found to have abnormalities during their health check-ups at iKang, iKang can provide recommendations for green channel medical services. If cancer is diagnosed, iKang offers free secondary diagnosis and treatment evaluation services by experts of associate chief physician level or above from any Grade A tertiary hospital nationwide.。

iKang, in partnership with its strategic ally Haodf Online, enables clients to access over 150,000 renowned medical experts across China through the platform. Additionally, via WorldCare, an institution providing international second medical opinion services originating from Massachusetts General Hospital (affiliated with Harvard Medical School), clients can tap into the resources of more than 18,000 top-tier medical specialists in the United States. This network includes many of the world’s leading medical centers, such as Massachusetts General Hospital (affiliated with Harvard Medical School), Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Boston Children’s Hospital, Mayo Clinic, and UCLA Health.

Furthermore, through iKang’s Daoyitong platform, patients are assisted in securing appointment registrations with specialists at nearly 400 Grade A tertiary hospitals across China.

We can see that the product upgrades at iKang are underpinned by technologies such as liquid biopsy, genetic testing, artificial intelligence, smart hardware, and in vitro diagnostics. Achieving excellence in all these areas is beyond the capacity of any single company, including iKang; therefore, iKang also requires collaboration and support from industry leaders.

At this iKang strategic press conference, Zhang Ligang announced the iKangPartners+ initiative, under which iKang aims to collaborate with leading domestic and international brands providing in vitro diagnostics, medical equipment, second-opinion services, medical consultations, and insurance services, as well as with authoritative industry academic institutions and organizations.

iKang's partners include:

iKangPartners+Precision Medicine in In Vitro DiagnosticsPartners: New Horizon Health, Weizhen Group, Southern Gene, Topgen Diagnostics, Fosun Changzheng, Sekisui Chuangge, Becton Dickinson, and Roche.

iKangPartners+Medical Devices and Precision MedicinePartners: GE, Philips, Siemens, Beckman, Olympus, Fujifilm Healthcare, Yitijiankang.

iKangPartners+Second Opinion and Consultation ServicesPartners: Haodf, WorldCare, Shenmin Medical

iKangPartners+Insurance IndustryPartners: Aon, Mercer, MSH China, and other players in the insurance and brokerage industries.

iKangPartners+Medical NetworkPartners: Regional chain health checkup service providers Xinhua Zhuoyue, Puhui Health Checkup, and Minzhong Health Checkup. These three chain health checkup institutions collectively cover 31 cities and operate 44 health checkup centers, complementing iKang’s own health checkup centers.

iKangPartners+Industry OrganizationsPartners: Chinese Society of Health Management, Chinese Health Promotion Foundation, Beijing Health Management Association, Beijing Medical Association Health Management Branch, China Non-Public Medical Institutions Association, Tsinghua University Center for Public Health Research.